慢性粒细胞白血病的治疗进展

慢性粒细胞白血病(CML)是一种造血干细胞克隆性骨髓增殖性肿瘤.尽管酪氨酸激酶抑制剂(TKI)可抑制Bcr/Abl激酶活性,并在慢性期CML治疗中取得了很好的疗效,而且耐受性良好,但TKI有很多的不良反应.目前对于CML患者和社会而言,TKI的治疗已成为一个沉重的负担.因此,迫切需要探索清除来源于Ph+恶性干细胞克隆的CML微小残留病灶有望获得CML永久治愈和长期无病生存的方法,现就其治疗进展作一综述.

Advances in treatment of chronic myelogenous leukemia

Chronic myelogenous leukemia （CML） is one of clonal bone marrow hematopoietic stem cells proliferative tumors.Tyrosine kinase inhibitor （TKI） has good therapeutic effects in the treatment of CML by inhibiting the activity of Bcr/Abl kinase.However,TKI still has a lot of side effects,although it can be well tolerated.Currently,TKI treatment has become a heavy burden for both CML patients and the society.Therefore,to clear CML tiny residual lesions from Ph＋ malignantly clonal stem cells has become an urgent need,which is expected to be an effective method for CML patients to obtain permanent cure and long-term disease-free survival.On this regard,we review the main advances achieved in the treatment of CML.